Business Of Biotech Developing Novel Cancer Drugs On A Budget With Iterion Therapeutics' Rahul Aras, Ph.D.
Mar 9, 2026
Rahul Aras, Ph.D., biotech executive and CEO of Iterion Therapeutics, previously founded ventures in gene and regenerative therapies. He discusses advancing a novel Wnt/β-catenin-targeting cancer drug on a lean budget. Conversations cover clinical progress in HCC and desmoid tumors, capital-efficient trial design under $50M, combination strategies, and operating a biotech from Houston.
AI Snips
Chapters
Transcript
Episode notes
Limit Variables And Seek Near Term Gates
- Minimize variables in early programs and pick indications with clear near-term value inflection points.
- Avoid projects with multiple novel unknowns like new modality, delivery device, and lacking biomarkers at once.
Capital Efficient Pathway From Concept To Clinic
- Iterion progressed from concept to human proof-of-concept in desmoid tumors and HCC with under $50M equity plus $26M in grants.
- Rahul Aras credits focused indication choice, CRPIT funding, and avoiding broad basket trials for capital efficiency.
Clinicians Rapidly Referred Patients After Early Signals
- As Iterion's HCC trial progressed, centers began pre-screening HCC patients for Wnt-beta mutations and filled new cohorts within ~48 hours.
- Rapid physician outreach occurred because Tagovivint showed tolerability and monotherapy activity.